Biomedical Engineering Reference
In-Depth Information
Fig. 1. Example of allele-specific oligonucleotide dot blot hybridization results.
Lane 1,: wild-type control; lane 2, homoplasmic mutant control; lane 3, no DNA
template control; lane 4, heteroplasmic mutant control; lane 5, sample with wild-type
mitochondrial DNA; lane 6, sample with homoplasmic mutation; lane 7, sample with
heteroplasmic mutation; lane 8, sample DNA failed to amplify.
increasing the temperature may be necessary. If this is the case, gradually in-
crease the wash temperature by 2-4°C each time, until the background is low.
References
1.
Shoffner, J. and Wallace, D. (1995)
Oxidative phosphorylation diseases
, in.
McGraw-Hill, New York: pp. 1535-629.
2.
Smeitink, J., van den Heuvel, L., and DiMauro, S. (2001) The genetics and
pathology of oxidative phosphorylation. Nat.
Rev. Genet.
2,
342-352.
3.
Wallace, D. C. (1992) Diseases of the mitochondrial DNA.
Annu. Rev. Biochem.
61,
1175-1212.
4.
Wong, L. J. and Senadheera, D. (1997) Direct detection of multiple point muta-
tions in mitochondrial DNA.
Clin. Chem.
43,
1857-1861.
5.
Wong, L. J. and Lam, C. W. (1997) Alternative, noninvasive tissues for quantita-
tive screening of mutant mitochondrial DNA.
Clin. Chem.
43,
1241-1243.
6.
Lahiri, D. K. and Nurnberger, J. I., Jr. (1991) A rapid non-enzymatic method for
the preparation of HMW DNA from blood for RFLP studies.
Nucleic Acids Res.
19,
5444.
7.
Liang, M. H. and Wong, L. J. (1998) Yield of mtDNA mutation analysis in 2,000
patients.
Am. J. Med. Genet.
77,
395-400.
8.
Liang, M. H., Johnson, D. R., and Wong, L. J. (1998) Preparation and validation
of PCR-generated positive controls for diagnostic dot blotting.
Clin. Chem.
44,
1578-1579.
9.
DeMarchi, J. M., Richards, C. S., Fenwick, R. G., Pace, R., and Beaudet, A. L.
(1994) A robotics-assisted procedure for large scale cystic fibrosis mutation
analysis.
Hum. Mutat.
4,
281-290.
10.
DeMarchi, J. M., Beaudet, A. L., Caskey, C. T., and Richards, C. S. (1994) Expe-
rience of an academic reference laboratory using automation for analysis of cys-
tic fibrosis mutations.
Arch. Pathol. Lab. Med.
118,
26-32.
